

Focus

Development of novel therapeutics for the treatment of autoimmune diseases

Management

Peter Buckel

Chief Executive Officer

Peter Sondermann

Chief Scientific Officer

Sascha Tillmanns

Medical Director

Robert Phelps

Head Business Development & Licensing

Michael Kring*

Chief Financial Officer

* advisor

Board

Thomas Hecht

Chairman

Ernst-Günter Afting

Michael Motschmann

Markus Hosang

Ulrich Mahr

Scientific Advisory Board

Robert Huber

Chairman

Uwe Jacob

Christoph Huber

Helmut Lenz

Fritz Melchers

Zoltan Nagy

Falk Nimmerjahn

Jeffrey Ravetch

Key Shareholders

MIG AG

BioMedInvest AG

Santo Holding GmbH

ZETACUBE s.r.l.

KfW Mittelstandsbank

Bayern Kapital GmbH

Max-Planck-Gesellschaft e.V.

Contact details

SuppreMol GmbH

Am Klopferspitz 19

D-82152 Martinsried / Munich

Germany

Tel.: +49 (0)89 30 90 50 68 0

Fax: +49 (0)89 30 90 50 68 68

Email: info@suppremol.com

www.suppremol.com

Company Overview

SuppreMol GmbH is a privately held biotechnology company focusing on the development of novel therapeutics to treat autoimmune diseases, such as Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. In particular, the company specializes on the development of soluble Fcγ receptors (sFcγRs), which are recombinant autologous proteins with a proven strong immunosuppressive potential. SuppreMol was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry and is located in Martinsried near Munich, Germany.


Technology

In an autoimmune disease situation, immune cells start acting against the body's own organs, tissues, and cells after activation by so-called auto-immune complexes which act on Fcγ receptors (FcγRs) expressed on the immune cells. These FcγRs play a key role in modulating the immune system. Based on their strong immunoregulatory potential, SuppreMol has developed a novel concept for the treatment of autoimmune diseases. It uses soluble Fcγ receptors (sFcγRs) which compete with FcγRs expressed on immune cells and as a result prevent the onset of immune reactions very early before the fatal cascade of events starts. SuppreMol's treatment approach has therefore the potential to specifically suppress the impaired immune functions of the immune system rather than only treating symptoms of the disease. This is in contrast to currently available treatments which in addition are frequently associated with severe side effects.

Products

SuppreMol is developing soluble Fcγ receptors (sFcγRs) for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura (ITP), Systemic Lupus Erythematosus (SLE), and Rheumatoid Arthritis (RA). The company's lead program SM101, a soluble Fcγ receptor IIb (sFcγRIIb) proved to be safe and well tolerated in over 30 healthy volunteers as demonstrated in a Phase I trial and is currently in a Phase II proof-of-concept study to treat ITP. SuppreMol will also develop SM101 for SLE and, together with a future collaboration partner, for RA. The company also has early stage programs on further soluble Fc receptors and on Fc receptor blocking monoclonal antibodies.

Pipeline Overview



Collaborations

SuppreMol is looking for development collaborations for its product candidates, especially outside its first indication ITP, for which the company has been granted orphan drug designation (ODD) in Europe (EMA) and in the USA (FDA).

Investors

In May 2006, SuppreMol has closed a Series A financing round to fund product development of its lead product (SM101). Z-Cube, the venture capital subsidiary of the Zambon Group, provided EUR 1.5M equity, KfW another EUR 1.5M and Bayern Kapital EUR 1.0M.

In 2008, SuppreMol closed a EUR 15.7m Series B financing round with MIG AG, BioMedInvest, and Santo Holding as new investors. The company's existing investors also participated in the round.

The company is currently looking for an additional investor with an international focus to participate in a planned Series C financing round in mid-2010. SuppreMol intends to raise EUR 15 million in order to accelerate the clinical development of SM101 in ITP and SLE and to obtain clinical proof-of-concept by mid-2012. The company's existing investors are committed to also participate in the financing.